Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-1401, Poly-ICLC, Decitabine, and Nivolumab in MDS or Low Blast Count AML
NCT03358719Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2018
- Primary completion
- Feb 2020
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CDX-1401 in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Proportion of Participants Experiencing a Dose-limiting Toxicity up to 180 days. Started Mar 2018; status: completed.
02
Drugs
CDX-1401
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03358719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03358719.